RESULTS IN HER2+ EARLY BREAST CANCER
Why is PERJETA-based treatment used in early breast cancer before
The potential benefits and risks of PERJETA with Herceptin®
(trastuzumab) and docetaxel for HER2+ early breast cancer have been
studied in two clinical trials. Learn more about how doctors check to
see if a cancer is responding to treatment before surgery, and how
cancer treated with PERJETA-based treatment responded.
How your doctor will tell if your cancer is responding to
A pathologist checks the breast tissue and nodes removed during
surgery to see how well neoadjuvant treatment worked. Neoadjuvant
treatment is considered successful if cancer cells are not detected in
the breast and lymph nodes. This is called a pathological complete
A pathological complete response is not a cure. A pathological complete response can give some information about the cancer, but it may not change a treatment plan. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival.
More tumors had pathological complete response when given PERJETA
with Herceptin and docetaxel
PERJETA was studied in 2 clinical trials of more than 600 patients
with HER2-positive (HER2+) early breast cancer who received breast
cancer treatment before surgery. In those studies, more tumors had a
pathological complete response when PERJETA with Herceptin®
(trastuzumab) and docetaxel was given before surgery.
- In one trial, PERJETA, Herceptin, and docetaxel were given together before breast cancer surgery
- 39.3% of the breast tumors treated with this combination had a pathological complete response
- When PERJETA wasn’t included in the combination, 21.5% of breast tumors had a pathological complete response to treatment before surgery
PERJETA works with other medications to fight cancer before surgery
as part of a 1-year treatment course.
What does PERJETA treat?
PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival.
- The safety of PERJETA in combination with doxorubicin-containing regimens has not been established
- The safety of PERJETA administered for greater than 6 cycles for early-stage breast cancer has not been established
Side effects may occur with PERJETA
What are the most serious side effects of PERJETA?
Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are:
- Hair loss
- Low levels of white blood cells with or without a fever
Always report side effects to your healthcare team at any point in
You are encouraged to report side effects to Genentech and the FDA.
You may contact Genentech by calling 1-888-835-2555. You may contact
the FDA by visiting www.fda.gov/medwatch or calling